- Ros Deegan
- Professor Dame Carol Robinson
- % Shareholding
- Number of employees
- Raised in an expanded Series A financing in February 2020
Unless stated all data at 31 December 2020
OMass Therapeutics is an Oxford University spin-out backed by Syncona and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
OMass uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, focusing on membrane receptors.
The platform is based on work initiated by its scientific founders in the laboratory of Professor Carol Robinson at Oxford University and is currently being applied to G-protein coupled receptors and other membrane proteins where they have developed a portfolio of intellectual property protection. Omass are optimising and automating their approach and this is part-funded by an Innovate Grant, awarded in March 2018.
OMass have initiated programs against three high impact G-protein coupled receptor targets (GPCRs) with a focus on genetically defined patient populations and/or immunological dysfunction. Currently actively evaluating additional GPCRs and solute carriers aligned with their focus on immunology and genetic disease.
OMass’ strategy is to discover, develop and ultimately commercialise a pipeline of small molecule therapeutics that bring life-changing benefits to patients suffering from immunology and genetic disorders. They are open to strategic collaborations in high value areas where they can combine their proprietary technology with a partner’s biology expertise.
- Opportunity to develop differentiated small molecule drugs leveraging a world-leading Native Mass Spectrometry platform which enables unique insights into membrane proteins and protein complexes such as GPCRs and Solute Carriers – classes of targets that have been historically difficult to drug in spite of high clinical relevance and unmet need.
Unmet medical need
- Undisclosed programmes are all in indications with significant unmet medical need
- Attrition of potential drugs
The Omass Therapeutics pipeline